Breast Cancers of Special Histologic Subtypes Are Biologically Diverse
Authors:
- 9 August 2018
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 25 (11) , 3158-3164
Abstract
Cancers classified as “special histologic subtypes” are felt to have a good prognosis. We used the 21-gene Oncotype DX Breast Recurrence Score&Keywords
Funding Information
- NIH/NCI Cancer Center Support Grant (P30 CA008748)
This publication has 34 references indexed in Scilit:
- Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodesContemporary Clinical Trials, 2013
- Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast CancerJournal of Clinical Oncology, 2012
- Outcome of special types of luminal breast cancerAnnals of Oncology, 2011
- Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancersCancer, 2010
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical TrialsJournal of Clinical Oncology, 2008
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Prognosis in Infiltrating Lobular CarcinomaAmerican Journal of Surgical Pathology, 1990
- Infiltrating lobular carcinoma of the breastHistopathology, 1982